Pharmacia Somavert Manufacturing Changes Planned For U.S. Approval
Executive Summary
Pharmacia expects FDA approval of the acromegaly drug Somavert (pegvisomant) in the "next several months" pending clearance of a revised manufacturing process
You may also be interested in...
Pharmacia Somavert Clears FDA For Acromegaly; Liver Testing Recommended
Labeling for Pharmacia's acromegaly treatment Somavert recommends monthly liver function monitoring for the first six months of treatment
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011